Analyst Ratings For Acer Therapeutics Inc (NASDAQ:ACER)
Today, Acer Therapeutics Inc (NASDAQ:ACER) stock was downgraded by William Blair from Outperform to Market Perform.
There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Acer Therapeutics Inc (NASDAQ:ACER) is Buy with a consensus target price of $47.75 per share, a potential 1,074.66% upside.
Some recent analyst ratings include
- 6/25/2019-Acer Therapeutics Inc (NASDAQ:ACER) gets downgraded to Market Perform by William Blair
- 2/15/2019-Acer Therapeutics Inc (NASDAQ:ACER) has coverage initiated with a Outperform rating and $40.00 price target
- 12/20/2018-Acer Therapeutics Inc (NASDAQ:ACER) has coverage initiated with a Buy ➝ Buy rating and $48.00 price target
- 2/26/2018-Acer Therapeutics Inc (NASDAQ:ACER) has coverage initiated with a Buy ➝ Buy rating and $70.00 price target
- On 8/1/2018 Life Science Ventures Vii Tvm, Director, bought 275,000 with an average share price of $18.00 per share and the total transaction amounting to $4,950,000.00.
- On 12/14/2017 Steve Aselage, Director, bought 2,000 with an average share price of $12.00 per share and the total transaction amounting to $24,000.00.
- On 11/18/2016 Timothy C Barabe, Director, sold 14,914 with an average share price of $0.55 per share and the total transaction amounting to $8,202.70.
- On 9/17/2014 Timothy C Barabe, Director, bought 10,000 with an average share price of $1.15 per share and the total transaction amounting to $11,500.00.
- On 9/16/2014 Neil K Warma, CEO, bought 10,000 with an average share price of $1.11 per share and the total transaction amounting to $11,100.00.
- On 12/18/2013 Karthik Radhakrishnan, CFO, bought 8,000 with an average share price of $1.70 per share and the total transaction amounting to $13,600.00.
- On 12/18/2013 Scott B Seaman, Director, bought 30,000 with an average share price of $1.70 per share and the total transaction amounting to $51,000.00.
About Acer Therapeutics Inc (NASDAQ:ACER)
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. Read More…
Recent Trading Activity for Acer Therapeutics Inc (NASDAQ:ACER)
Shares of Acer Therapeutics Inc closed the previous trading session at 4.06 −15.22 78.92% with 3.83 shares trading hands.